A Multicenter, Open-Label, Noncomparative Phase I Clinical and Pharmacokinetic Study of Oral TAK-285 in Patients With Advanced Cancer.
Latest Information Update: 10 Nov 2021
At a glance
- Drugs TAK 285 (Primary)
- Indications Solid tumours
- Focus Adverse reactions; Pharmacokinetics
- 08 Dec 2011 Actual end date (Jun 2011) added as reported by ClinicalTrials.gov.
- 08 Dec 2011 Actual patient number is 56 according to ClinicalTrials.gov.
- 08 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.